Ann Rehabil Med.  2016 Jun;40(3):481-488. 10.5535/arm.2016.40.3.481.

Prediction of Functional Outcome in Axonal Guillain-Barre Syndrome

• Sung EJ
• Kim DY
• Chang MC
• Ko EJ

• KMID: 2327610
• DOI: http://doi.org/10.5535/arm.2016.40.3.481

Abstract

OBJECTIVE
To identify the factors that could predict the functional outcome in patients with the axonal type of Guillain-Barre syndrome (GBS).
METHODS
Two hundred and two GBS patients admitted to our university hospital between 2003 and 2014 were reviewed retrospectively. We defined a good outcome as being "able to walk independently at 1 month after onset" and a poor outcome as being "unable to walk independently at 1 month after onset". We evaluated the factors that differed between the good and poor outcome groups.
RESULTS
Twenty-four patients were classified into the acute motor axonal neuropathy type. There was a statistically significant difference between the good and poor outcome groups in terms of the GBS disability score at admission, and GBS disability score and Medical Research Council sum score at 1 month after admission. In an electrophysiologic analysis, the good outcome group showed greater amplitude of median, ulnar, deep peroneal, and posterior tibial nerve compound muscle action potentials (CMAP) and greater amplitude of median, ulnar, and superficial peroneal sensory nerve action potentials (SNAP) than the poor outcome group.
CONCLUSION
A lower GBS disability score at admission, high amplitude of median, ulnar, deep peroneal, and posterior tibial CMAPs, and high amplitude of median, ulnar, and superficial peroneal SNAPs were associated with being able to walk at 1 month in patients with axonal GBS.

Keyword

Guillain-Barre syndrome; Functional outcome; GBS disability score; MRC sum score; Acute motor axonal neuropathy

MeSH Terms

Action Potentials
Axons*
Guillain-Barre Syndrome*
Humans
Retrospective Studies
Tibial Nerve

Reference

1. Hughes RA, Cornblath DR. Guillain-Barre syndrome. Lancet. 2005; 366:1653–1666. PMID: 16271648.

2. van Doorn PA. Treatment of Guillain-Barre syndrome and CIDP. J Peripher Nerv Syst. 2005; 10:113–127. PMID: 15958124.

3. van Koningsveld R, Steyerberg EW, Hughes RA, Swan AV, van Doorn PA, Jacobs BC. A clinical prognostic scoring system for Guillain-Barre syndrome. Lancet Neurol. 2007; 6:589–594. PMID: 17537676.

4. McKhann GM, Cornblath DR, Griffin JW, Ho TW, Li CY, Jiang Z, et al. Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China. Ann Neurol. 1993; 33:333–342. PMID: 8489203.

5. Hafer-Macko CE, Sheikh KA, Li CY, Ho TW, Cornblath DR, McKhann GM, et al. Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy. Ann Neurol. 1996; 39:625–635. PMID: 8619548.

6. Hafer-Macko C, Hsieh ST, Li CY, Ho TW, Sheikh K, Cornblath DR, et al. Acute motor axonal neuropathy: an antibody-mediated attack on axolemma. Ann Neurol. 1996; 40:635–644. PMID: 8871584.

7. Hiraga A, Kuwabara S, Ogawara K, Misawa S, Kanesaka T, Koga M, et al. Patterns and serial changes in electrodiagnostic abnormalities of axonal Guillain-Barre syndrome. Neurology. 2005; 64:856–860. PMID: 15753422.

8. Feasby TE, Gilbert JJ, Brown WF, Bolton CF, Hahn AF, Koopman WF, et al. An acute axonal form of Guillain-Barre polyneuropathy. Brain. 1986; 109(Pt 6):1115–1126. PMID: 3790970.

9. Wee AS, Abernathy SD. The sural sensory nerve is usually spared in Guillain-Barre syndrome. J Miss State Med Assoc. 2003; 44:251–255. PMID: 14531230.

10. Hiraga A, Mori M, Ogawara K, Hattori T, Kuwabara S. Differences in patterns of progression in demyelinating and axonal Guillain-Barre syndromes. Neurology. 2003; 61:471–474. PMID: 12939419.

11. Hiraga A, Mori M, Ogawara K, Kojima S, Kanesaka T, Misawa S, et al. Recovery patterns and long term prognosis for axonal Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry. 2005; 76:719–722. PMID: 15834034.

12. Tamura N, Kuwabara S, Misawa S, Kanai K, Nakata M, Sawai S, et al. Time course of axonal regeneration in acute motor axonal neuropathy. Muscle Nerve. 2007; 35:793–795. PMID: 17221880.

13. Kuwabara S, Asahina M, Koga M, Mori M, Yuki N, Hattori T. Two patterns of clinical recovery in Guillain-Barre syndrome with IgG anti-GM1 antibody. Neurology. 1998; 51:1656–1660. PMID: 9855518.

14. McKhann GM, Griffin JW, Cornblath DR, Mellits ED, Fisher RS, Quaskey SA. Plasmapheresis and Guillain-Barre syndrome: analysis of prognostic factors and the effect of plasmapheresis. Ann Neurol. 1988; 23:347–353. PMID: 3382169.

15. Visser LH, Schmitz PI, Meulstee J, van Doorn PA, van der Meche FG. Prognostic factors of Guillain-Barre syndrome after intravenous immunoglobulin or plasma exchange. Dutch Guillain-Barre Study Group. Neurology. 1999; 53:598–604. PMID: 10449126.

16. Chio A, Cocito D, Leone M, Giordana MT, Mora G, Mutani R, et al. Guillain-Barre syndrome: a prospective, population-based incidence and outcome survey. Neurology. 2003; 60:1146–1150. PMID: 12682322.

17. Hadden RD, Karch H, Hartung HP, Zielasek J, Weissbrich B, Schubert J, et al. Preceding infections, immune factors, and outcome in Guillain-Barre syndrome. Neurology. 2001; 56:758–765. PMID: 11274311.

18. The prognosis and main prognostic indicators of Guillain-Barre syndrome: a multicentre prospective study of 297 patients. The Italian Guillain-Barre Study Group. Brain. 1996; 119(Pt 6):2053–2061. PMID: 9010009.

19. A prospective study on the incidence and prognosis of Guillain-Barre syndrome in Emilia-Romagna region, Italy (1992-1993). Emilia-Romagna Study Group on Clinical and Epidemiological Problems in Neurology. Neurology. 1997; 48:214–221. PMID: 9008520.

20. Jacobs BC, van Doorn PA, Schmitz PI, Tio-Gillen AP, Herbrink P, Visser LH, et al. Campylobacter jejuni infections and anti-GM1 antibodies in Guillain-Barre syndrome. Ann Neurol. 1996; 40:181–187. PMID: 8773599.

21. Rees JH, Soudain SE, Gregson NA, Hughes RA. Campylobacter jejuni infection and Guillain-Barre syndrome. N Engl J Med. 1995; 333:1374–1379. PMID: 7477117.

22. Kuwabara S, Yuki N, Koga M, Hattori T, Matsuura D, Miyake M, et al. IgG anti-GM1 antibody is associated with reversible conduction failure and axonal degeneration in Guillain-Barre syndrome. Ann Neurol. 1998; 44:202–208. PMID: 9708542.

23. Ho TW, Mishu B, Li CY, Gao CY, Cornblath DR, Griffin JW, et al. Guillain-Barre syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain. 1995; 118(Pt 3):597–605. PMID: 7600081.

24. Ogawara K, Kuwabara S, Mori M, Hattori T, Koga M, Yuki N. Axonal Guillain-Barre syndrome: relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan. Ann Neurol. 2000; 48:624–631. PMID: 11026446.

25. Kuwabara S, Yuki N. Axonal Guillain-Barre syndrome: concepts and controversies. Lancet Neurol. 2013; 12:1180–1188. PMID: 24229616.

26. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barre syndrome. Ann Neurol. 1990; 27(Suppl):S21–S24. PMID: 2194422.

27. Van den Bergh PY, Pieret F. Electrodiagnostic criteria for acute and chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve. 2004; 29:565–574. PMID: 15052622.

28. van der Meche FG, Schmitz PI. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. Dutch Guillain-Barre Study Group. N Engl J Med. 1992; 326:1123–1129. PMID: 1552913.

29. Walgaard C, Lingsma HF, Ruts L, van Doorn PA, Steyerberg EW, Jacobs BC. Early recognition of poor prognosis in Guillain-Barre syndrome. Neurology. 2011; 76:968–975. PMID: 21403108.

30. Double-blind trial of intravenous methylprednisolone in Guillain-Barre syndrome. Guillain-Barre Syndrome Steroid Trial Group. Lancet. 1993; 341:586–590. PMID: 8094828.

31. Kleyweg RP, van der Meche FG, Schmitz PI. Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barre syndrome. Muscle Nerve. 1991; 14:1103–1109. PMID: 1745285.

32. Hughes RA, Newsom-Davis JM, Perkin GD, Pierce JM. Controlled trial prednisolone in acute polyneuropathy. Lancet. 1978; 2:750–753. PMID: 80682.

33. Islam Z, Jacobs BC, van Belkum A, Mohammad QD, Islam MB, Herbrink P, et al. Axonal variant of Guillain-Barre syndrome associated with Campylobacter infection in Bangladesh. Neurology. 2010; 74:581–587. PMID: 20157160.

34. Cornblath DR, Mellits ED, Griffin JW, McKhann GM, Albers JW, Miller RG, et al. Motor conduction studies in Guillain-Barre syndrome: description and prognostic value. Ann Neurol. 1988; 23:354–359. PMID: 3382170.

35. Miller RG, Peterson GW, Daube JR, Albers JW. Prognostic value of electrodiagnosis in Guillain-Barre syndrome. Muscle Nerve. 1988; 11:769–774. PMID: 3405243.